We could be underestimating the impact of obesity on breast cancer risk

Publicly released:
International
Photo by Siora Photography on Unsplash
Photo by Siora Photography on Unsplash

The link between obesity and a higher breast cancer risk could be stronger than we think, according to international researchers who investigated the association using two different ways of measuring obesity. Using data from a cancer study, the researchers measured both BMI - the height and weight index often used to measure overweight/obesity in research - and body fat percentage among just over 1000 postmenopausal women with breast cancer and over 1100 women of a similar demographic without breast cancer. The researchers say the link between higher body fat percentage and breast cancer risk was stronger than the link between BMI and breast cancer, suggesting previous research may have underestimated the impact of overweight/obesity on a woman's breast cancer risk.

Media release

From: BMJ Group

JOURNAL OF EPIDEMIOLOGY & COMMUNITY HEALTH

Externally peer reviewed? Yes
Evidence type: Case-control study
Subjects: People

Around 40% of postmenopausal hormone positive breast cancers linked to excess body fat

Proportion much higher than that assessed with widely used measure (BMI)
Real impact of obesity on risk has likely been underestimated, say researchers

Around 40% of postmenopausal hormone positive breast cancer cases may be linked to excess body fat, suggests Spanish research published online in the Journal of Epidemiology & Community Health.

This proportion is significantly higher than 1 in 10 such cases currently attributed to excess weight, using the widely used measure of body mass index (BMI), and indicates that the real impact of obesity on breast cancer risk has likely been underestimated, say the researchers.

BMI isn’t necessarily a very accurate measure of body fat, particularly in older women, because it doesn’t account for age, sex, or ethnicity, they point out.

They therefore compared BMI with the CUN-BAE (Clínica Universidad de Navarra–Body Adiposity Estimator), a validated measure of body fat that does account for age and sex, in 1033 White postmenopausal women with breast cancer and 1143 free of the disease, but matched for age, sex, and geographical region.

All the women were taking part in the multicase-control (MCC)-Spain study, which aims to evaluate the environmental and genetic factors associated with bowel, breast, stomach, and prostate cancers and chronic lymphocytic leukaemia among 20-85 year olds.

All participants were quizzed on potentially influential risk factors: sociodemographics; lifestyle; and personal/family medical and reproductive histories.

Dietary information was collected through a validated semi structured 140-item Food Frequency Questionnaire, and a self-administered questionnaire was used to gather information on usual alcohol intake between the ages of 30 and 40.

The CUN-BAE categorises body fat as: less than 35%; 35%–39.9%; 40%–44.9%; and 45% and above. BMI classifies weight as: less than 25 kg/m2; 25–29.9; 30–34.9; and 35 and above.

Average BMI was just over 26 in the comparison group and just over 27 in the women with breast cancer. Average CUN-BAE was just under 40% and almost 40.5%, respectively.

A BMI below 25 (reference) was observed in 45% of women in the comparison group and in 37% of those with breast cancer. A BMI of 30 or above, which signifies obesity, was observed in 20% and in just over 24%, respectively.

A CUN-BAE below 35% (reference) was observed in 20.5% of women in the comparison group and in 16% of those with breast cancer. A CUN-BAE of 40% or above was observed in just over 46% of women in the comparison group and in 53% of those with breast cancer.

A CUN-BAE of 45% or above was associated with a more than doubling in the risk of postmenopausal breast cancer compared with a CUN-BAE of below 35%.

No similar trend was observed for BMI, prompting the researchers to estimate that 23% of breast cancer cases were attributable to excess body fat using BMI, but 38% using the CUN-BAE.

But these differences were only apparent for hormone positive cancers (680 cases) for which the estimated proportions attributable to excess body fat were 20% (BMI) and 42% (CUN-BAE).

Causal factors can’t be established from the findings of this case-control study, say the researchers, who also acknowledge that the CUN-BAE formula was calculated from a sample of sedentary people; and the number of breast cancers that weren’t hormone positive was small.

Nevertheless, they conclude: “The results of our study indicate that excess body fat is a significant risk factor for hormone receptor positive breast cancer in postmenopausal women.

“Our findings suggest that the population impact could be underestimated when using traditional BMI estimates, and that more accurate measures of body fat, such as CUN-BAE, should be considered when estimating the cancer burden attributable to obesity in postmenopausal breast cancer.”

This is crucial for planning effective prevention initiatives, they add.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research BMJ Group, Web page The URL will go live after the embargo ends
Journal/
conference:
Journal of Epidemiology & Community Health
Research:Paper
Organisation/s: University of León Institute of Biomedicine, Spain
Funder: This research was supported by Acción Transversal del Cáncer (approved by the Spanish Council of Ministers on 11 October 2007), Carlos III Health Institute-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286, PS09/01903, PS09/02078, PS09/01662, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/0613, PI15/00069, PI15/00914, PI15/01032, PI11/01810, PI14/01219, PI11/02213, PIE16/00049, PI17/01179, PI17/00092), Fundación Marqués de Valdecilla (API 10/09), ICGC International Cancer Genome Consortium CLL (the ICGC CLL-Genome Project is funded by the Spanish Ministry of Economy and Competitiveness through the Carlos III Health Institute (ISCIII)), ISCIII Red Temática de Investigación del Cáncer (RTICC) (RD12/0036/0036), Regional Government of Castilla y León (LE22A10-2), Regional Health Ministry of Andalucía (PI-0571- 2009, PI-0306- 2011, salud201200057018tra), Regional Health Ministry of Valencia (AP_061/10), Recercaixa (2010ACUP00310), Regional Government of the Basque Country, Regional Health Ministry of Murcia, European Commission (grants FOOD-CT- 2006– 036224-HIWATE), Spanish Association Against Cancer (AECC) Scientific Foundation (GCTRA18022MORE), Agency for Management of University and Research Grants (AGAUR) of the Catalan Regional Government (2014SGR647, 2014SGR850 and 2017SGR723), Fundación Caja de Ahorros de Asturias and University of Oviedo. ISGlobal is a member of the CERCA Program, Regional Government of Catalonia. VD-B is contracted with the competitive national postdoctoral ’Sara Borrell’ fellowship programme (CD21/00025) funded by Instituto de Salud Carlos III (ISCIII) and the European Regional Development Funds/European Social Fund.
Media Contact/s
Contact details are only visible to registered journalists.